Get started
AstraZeneca PLCAstraZeneca PLCAstraZeneca PLC

AstraZeneca PLC

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsBondsETFs

Chart


Full chart

Key facts today


AstraZeneca reported that the Hickory trial of efzimfotase alfa demonstrated a numerical improvement in the primary endpoint but did not achieve statistical significance.
AstraZeneca (AZN) shares rose ~1% to 14,798p at 09:00 BST after Rare Disease unit CEO Marc Dunoyer noted positive potential across patient populations; traders should note price and sector update.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪221.80 B‬ GBP
Dividend yield (indicated)
1.71%
Price to earnings Ratio (TTM)
28
Basic EPS (TTM)
6 GBP
Net income (FY)
‪7.76 B‬ GBP
Revenue (FY)
‪44.57 B‬ GBP
Shares float
‪1.48 B‬
Beta (1Y)
1.07

Employees


Employees (FY)
‪96.1 K‬
Change (1Y)
‪+1.8 K‬ +1.91%
Revenue / Employee (1Y)
‪463.79 K‬ GBP
Net income / Employee (1Y)
‪80.73 K‬ GBP

About AstraZeneca PLC


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Pascal Soriot
Website
astrazeneca.com
Headquarters
Cambridge
Founded
1913
IPO date
Sep 21, 2007
Identifiers
2
ISIN GB0009895292
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Check out other big names from the same industry as AZN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


5.549% YTM
Maturity date Aug 17, 2048
Coupon 4.38% (Fixed)
5.543% YTM
Maturity date May 28, 2051
Coupon 3.00% (Fixed)
5.540% YTM
Maturity date Aug 6, 2050
Coupon 2.13% (Fixed)
5.525% YTM
Maturity date Nov 16, 2045
Coupon 4.38% (Fixed)
5.513% YTM
Maturity date Sep 18, 2042
Coupon 4.00% (Fixed)
5.132% YTM
Maturity date Sep 15, 2037
Coupon 6.45% (Fixed)
4.963% YTM
Maturity date Apr 8, 2026
Coupon 0.70% (Fixed)
4.927% YTM
Maturity date Mar 2, 2036
Coupon 4.60% (Fixed)
4.869% YTM
Maturity date Nov 13, 2031
Coupon 5.75% (Fixed)
4.756% YTM
Maturity date Feb 26, 2034
Coupon 5.00% (Fixed)
4.683% YTM
Maturity date Mar 2, 2033
Coupon 4.30% (Fixed)

See all AZN bonds 

ETFs holding the stock


VXUS
Vanguard Total International Stock ETF
Weight 0.71%
Market value ‪4.62 B‬
VEA
Vanguard FTSE Developed Markets ETF
Weight 0.97%
Market value ‪3.03 B‬
IEFA
iShares Core MSCI EAFE ETF
Weight 1.26%
Market value ‪2.06 B‬
ISF
iShares Core FTSE 100 UCITS ETF GBP (Dist)
Weight 8.95%
Market value ‪1.70 B‬
ISFD
iShares PLC - iShares Core FTSE 100 UCITS ETF Accum Hedged USD
Weight 8.95%
Market value ‪1.70 B‬
CEB4
iShares Core FTSE 100 UCITS ETF Accum Shs Hedged EUR
Weight 8.95%
Market value ‪1.70 B‬
EFA
iShares MSCI EAFE ETF
Weight 1.47%
Market value ‪1.01 B‬
VGK
Vanguard FTSEEuropean ETF
Weight 1.94%
Market value ‪800.97 M‬
VEU
Vanguard FTSE All World Ex US ETF
Weight 0.78%
Market value ‪718.28 M‬
SCHF
Schwab International Equity ETF
Weight 1.05%
Market value ‪598.99 M‬
IWDG
iShares Core MSCI World UCITS ETF Hedged GBP
Weight 0.36%
Market value ‪451.53 M‬

Explore more ETFs 

Frequently asked questions


The current price of AZN is 14,726 GBX — it has increased by 2.80% in the past 24 hours. Watch AstraZeneca PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange AstraZeneca PLC stocks are traded under the ticker AZN.
AZN stock has risen by 7.36% compared to the previous week, the month change is a −3.25% fall, over the last year AstraZeneca PLC has showed a 29.95% increase.
We've gathered analysts' opinions on AstraZeneca PLC future price: according to them, AZN price has a max estimate of 20,601.29 GBX and a min estimate of 11,582.85 GBX. Watch AZN chart and read a more detailed AstraZeneca PLC stock forecast: see what analysts think of AstraZeneca PLC and suggest that you do with its stocks.
AZN reached its all-time high on Feb 18, 2026 with the price of 15,730 GBX, and its all-time low was 1,744 GBX and was reached on Mar 17, 2008. View more price dynamics on AZN chart.
See other stocks reaching their highest and lowest prices.
AZN stock is 1.17% volatile and has beta coefficient of 1.07. Track AstraZeneca PLC stock price on the chart and check out the list of the most volatile stocks — is AstraZeneca PLC there?
Today AstraZeneca PLC has the market capitalization of ‪221.80 B‬, it has decreased by −0.35% over the last week.
Yes, you can track AstraZeneca PLC financials in yearly and quarterly reports right on TradingView.
AstraZeneca PLC is going to release the next earnings report on Apr 29, 2026. Keep track of upcoming events with our Earnings Calendar.
AZN earnings for the last quarter are 1.57 GBX per share, whereas the estimation was 1.55 GBX resulting in a 1.45% surprise. The estimated earnings for the next quarter are 1.91 GBX per share. See more details about AstraZeneca PLC earnings.
AstraZeneca PLC revenue for the last quarter amounts to ‪11.51 B‬ GBX, despite the estimated figure of ‪11.46 B‬ GBX. In the next quarter, revenue is expected to reach ‪11.18 B‬ GBX.
AZN net income for the last quarter is ‪1.75 B‬ GBP, while the quarter before that showed ‪1.88 B‬ GBP of net income which accounts for 0.00% change. Track more AstraZeneca PLC financial stats to get the full picture.
Yes, AZN dividends are paid semi-annually. The last dividend per share was 1.60 GBP. As of today, Dividend Yield (TTM)% is 1.65%. Tracking AstraZeneca PLC dividends might help you take more informed decisions.
AstraZeneca PLC dividend yield was 1.71% in 2025, and payout ratio reached 47.19%. The year before the numbers were 2.35% and 69.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Mar 31, 2026, the company has ‪96.1 K‬ employees. See our rating of the largest employees — is AstraZeneca PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AstraZeneca PLC EBITDA is ‪14.68 B‬ GBP, and current EBITDA margin is 33.19%. See more stats in AstraZeneca PLC financial statements.
Like other stocks, AZN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AstraZeneca PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AstraZeneca PLC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AstraZeneca PLC stock shows the buy signal. See more of AstraZeneca PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.